Inspire Medical (INSP) Q2 Revenue Up 11%

Inspire Medical Systems (INSP) reported robust Q2 2025 results, with GAAP revenue of $217.1 million, an 11% year-over-year increase, and non-GAAP EPS of $0.45, both significantly surpassing consensus estimates. However, the company concurrently lowered its full-year 2025 revenue guidance to $900-910 million and diluted net income per share to $0.40-0.50, attributing the reduction to a slower-than-expected commercial transition to its new Inspire V device and associated inventory and operational headwinds. This guidance cut signals short-term execution challenges despite strong quarterly performance and ongoing product innovation.

Analysis

Inspire Medical Systems (INSP) reported a quarter of conflicting signals, characterized by a strong top-and-bottom-line beat for Q2 2025 that was materially overshadowed by a significant reduction in full-year guidance. The company posted Q2 GAAP revenue of $217.1 million, an 11% year-over-year increase that surpassed expectations, while non-GAAP EPS of $0.45 more than doubled consensus estimates. This performance was driven by continued growth in the U.S. (up 10%) and internationally (up 23%). However, management sharply lowered its full-year 2025 revenue forecast to $900-$910 million, down from $940-$955 million, and slashed its GAAP diluted net income per share outlook to $0.40-$0.50 from a prior $2.20-$2.30. This revision stems directly from operational headwinds related to a slower-than-expected commercial transition to its next-generation Inspire V device, as customers deplete existing Inspire IV inventory. The transition challenges are reflected in a GAAP net loss of $3.6 million, impacted by a $2.1 million inventory charge and other one-time expenses, and a significant rise in inventory to $121.6 million. Despite these execution issues, the company's fundamental market position remains intact, supported by favorable reimbursement coverage and its status as the only FDA-approved neurostimulation device for obstructive sleep apnea.

Key Decisions for Investors

• Investors should weigh the strong current demand, evidenced by the Q2 revenue and EPS beat, against the significant operational headwinds and execution risks highlighted by the severe full-year guidance cut.
• It is critical to monitor the pace of the Inspire V commercial rollout and the company's ability to manage its elevated inventory levels, as these are the primary drivers of the revised, lower outlook.
• While the market will likely react negatively to the guidance reduction, long-term investors should assess whether these are temporary transitional issues or indicative of deeper problems, considering the company's unique market position and strong underlying gross margins.
• Given the decline in cash from $516.5 million to $410.7 million in six months, scrutiny of cash burn and progress toward sustainable GAAP profitability is warranted in subsequent quarters.